Arlen Philip M, Gulley James L
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892-1750, USA.
Curr Opin Investig Drugs. 2005 Jun;6(6):592-6.
Prostate cancer is the most common, non-cutaneous cancer and the second leading cause of cancer death among men in the US. A greater understanding of basic immunological principles has led to the development of a variety of new techniques, which in turn has led to advances in the field of prostate cancer vaccines. This review will discuss the rationale for the development of vaccines involving whole tumor cells and dendritic cells, as well as pox viral vectors, and will summarize selected clinical studies that have incorporated these strategies.
前列腺癌是美国最常见的非皮肤癌，也是男性癌症死亡的第二大主要原因。对基本免疫学原理的更深入理解推动了多种新技术的发展，进而促进了前列腺癌疫苗领域的进步。本综述将讨论涉及全肿瘤细胞、树突状细胞以及痘病毒载体的疫苗研发原理，并总结纳入这些策略的部分临床研究。
